Exploiting Synthetic Lethality and Network Biology to Overcome EGFR Inhibitor Resistance in Lung Cancer.
about
Quantitative phosphoproteomic analysis of acquired cancer drug resistance to pazopanib and dasatinib.Candidate synthetic lethality partners to PARP inhibitors in the treatment of ovarian clear cell cancer.Improved detection of synthetic lethal interactions in Drosophila cells using variable dose analysis (VDA).Exploiting vulnerabilities in cancer signalling networks to combat targeted therapy resistance
P2860
Exploiting Synthetic Lethality and Network Biology to Overcome EGFR Inhibitor Resistance in Lung Cancer.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Exploiting Synthetic Lethality ...... tor Resistance in Lung Cancer.
@en
Exploiting Synthetic Lethality ...... tor Resistance in Lung Cancer.
@nl
type
label
Exploiting Synthetic Lethality ...... tor Resistance in Lung Cancer.
@en
Exploiting Synthetic Lethality ...... tor Resistance in Lung Cancer.
@nl
prefLabel
Exploiting Synthetic Lethality ...... tor Resistance in Lung Cancer.
@en
Exploiting Synthetic Lethality ...... tor Resistance in Lung Cancer.
@nl
P2860
P1476
Exploiting Synthetic Lethality ...... itor Resistance in Lung Cancer
@en
P2093
Annie Howitt
P2860
P304
P356
10.1016/J.JMB.2017.04.018
P407
P577
2017-05-03T00:00:00Z